Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $49.70
    -0.95 (-1.88%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Travere Therapeutics Inc (TVTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Travere Therapeutics reported revenue of $490.73M for the fiscal year ended Dec 31, 2025, up 110.5% from the year before. That year, net income was -$25.55M with a net margin of -5.2%, operating cash flow was $37.78M and free cash flow was -$20.37M. The quarter ended Sep 30, 2026 had revenue of $224.56M and net income of -$52.34M.

    Revenue and Margins

    The operating margin was -12.8% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $133.59M, a compound annual rate of 15.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$490.73M+110.5%97.9%-12.8%-5.2%
    Dec 2024$233.18M+60.5%96.7%-138.9%-137.9%
    Dec 2023$145.24M+32.7%92.1%-267.2%-76.7%
    Dec 2022$109.46M-17.0%96.0%-292.2%-254.4%
    Dec 2021$131.84M-33.5%97.1%-151.3%-136.6%
    Dec 2020$198.32M+13.1%96.9%-88.8%-85.4%
    Dec 2019$175.34M+6.8%97.0%-56.9%-83.5%
    Dec 2018$164.25M+6.0%96.6%-48.7%-62.5%
    Dec 2017$154.94M+16.0%97.7%-34.7%-38.6%
    Dec 2016$133.59MN/A96.6%-43.6%-35.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$490.73M$233.18M$145.24M$109.46M$131.84M$198.32M$175.34M$164.25M$154.94M$133.59M
    Cost of revenue$10.34M$7.74M$11.45M$4.42M$3.82M$6.13M$5.23M$5.53M$3.60M$4.55M
    Gross profit$480.39M$225.43M$133.79M$105.04M$128.02M$192.19M$170.10M$158.72M$151.33M$129.04M
    Research and development$206.01M$282.70M$244.99M$227.33M$201.16M$131.77M$140.96M$123.76M$78.17M$70.85M
    Operating income-$62.82M-$323.83M-$388.14M-$319.81M-$199.43M-$176.16M-$99.81M-$80.04M-$53.79M-$58.21M
    Net income-$25.55M-$321.55M-$111.40M-$278.48M-$180.09M-$169.43M-$146.43M-$102.68M-$59.73M-$47.90M
    EBITDA$22.22M-$265.77M-$326.25M-$299.42M-$184.46M-$145.16MN/A-$73.39M-$38.67M-$38.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$224.56M$169.58M$127.20M$129.69M$164.86M$114.45M$81.73M$74.79M$62.90M$54.12M$41.37M$45.06M
    Gross profit$221.70M$167.41M$100.43M$127.14M$163.27M$112.93M$77.05M$72.23M$61.27M$41.71M$39.87M$28.64M
    Operating income-$68.11M$3.95M-$36.91M-$32.43M$24.93M-$12.65M-$42.67M-$60.74M-$56.15M-$67.05M-$139.24M-$82.84M
    Net income-$52.34M-$34.80M-$37.10M$2.73M$25.71M-$12.76M-$41.23M-$60.26M-$54.81M-$70.41M-$136.06M-$90.17M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $317.60M exceeded cash and equivalents by $224.56M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$605.19M$594.13M$788.91M$672.59M$776.63M$607.44M$604.80M$709.16M$520.35M$525.28M
    Current assets$437.56M$416.70M$616.77M$486.44M$582.83M$410.41M$429.06M$495.68M$325.81M$332.35M
    Cash and equivalents$93.03M$58.53M$58.18M$61.69M$165.75M$84.77M$62.44M$102.87M$99.39M$41.00M
    Total liabilities$490.36M$535.05M$588.10M$629.73M$474.52M$396.23M$383.60M$390.91M$227.21M$217.51M
    Short-term debt$5.88M$74.08M$4.91M$4.43M$3.91M$357.00K$2.61M$22.46MN/AN/A
    Long-term debt$311.72M$310.31M$377.26M$375.55M$226.58M$215.34M$204.86M$195.09M$45.08MN/A
    Shareholder equity$114.83M$59.08M$200.81M$42.85M$302.11M$211.21M$221.20M$318.25M$293.13M$307.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$848.23M$799.36M$555.19M$605.19M$538.58M$555.31M$548.80M$594.13M$504.41M$551.12M$663.55M$788.91M
    Total liabilities$825.64M$774.84M$456.46M$490.36M$465.02M$522.56M$515.98M$535.05M$534.86M$535.97M$589.48M$588.10M
    Cash and equivalents$123.54M$117.73M$78.36M$93.03M$110.93M$75.15M$61.90M$58.53M$36.41M$32.29M$43.25M$58.18M
    Shareholder equity$22.58M$24.52M$98.73M$114.83M$73.56M$32.75M$32.82M$59.08M-$30.45M$15.15M$74.07M$200.81M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$37.78M-$237.47M-$280.02M-$186.29M-$14.79M-$42.74M-$58.21M-$24.96M$7.40M-$1.60M
    Capital expenditures$58.16M$101.21M$41.59M$28.37M$24.15M$119.84M$15.56M$19.70M$14.01M$11.92M
    Free cash flow-$20.37M-$338.69M-$321.61M-$214.66M-$38.94M-$162.59M-$73.78M-$44.66M-$6.61M-$13.52M
    Investing cash flow$27.89M$99.33M$55.78M-$32.55M-$137.62M-$61.33M$19.86M-$203.29M$45.60M$10.37M
    Financing cash flow-$33.47M$139.42M$218.75M$117.57M$231.68M$127.71M-$2.08M$231.86M$5.45M-$5.69M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$98.20M$58.07M-$40.37M$60.68M$14.32M$4.98M-$42.19M-$35.72M-$42.51M-$40.24M-$119.00M-$70.47M
    Capital expenditures$22.18M$22.18M$22.18M$18.86M$140.00K$235.00K$11.78M$9.56M$8.19M$11.99M$6.47M$5.53M
    Free cash flow$76.03M$35.89M-$62.54M$41.81M$14.18M$4.75M-$53.98M-$45.28M-$50.70M-$52.24M-$125.47M-$76.00M
    Last 12 quarters

    Frequently Asked Questions About TVTX

    What is Travere Therapeutics' annual revenue?

    Travere Therapeutics reported revenue of $490.73M for the fiscal year ended Dec 31, 2025.

    How fast is Travere Therapeutics' revenue growing?

    Revenue was up 110.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 64.9%.

    Is Travere Therapeutics profitable?

    No. Travere Therapeutics reported net income of -$25.55M for the fiscal year ended Dec 31, 2025, with a net margin of -5.2%.

    How much free cash flow does TVTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $37.78M minus capital expenditures of $58.16M produced free cash flow of -$20.37M.

    How much debt does Travere Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $311.72M, short-term debt of $5.88M and cash and equivalents of $93.03M.